title: [A case of cecum colon cancer with lymph node metastasis successfully treated with XELOX plus bevacizumab].
abstract: A 65-year-old woman with a history of constipation presented at our hospital and was subsequently diagnosed with advanced cecum cancer. We performed laparoscopic right hemicolectomy in January 2009, with pathological findings reveal- ing the presence of Stage III b (pT3, pN3, cM0, Cur A) disease. The patient was treated with a uracil/tegafur plus Leucovorin (UFT/LV) adjuvant chemotherapy regimen for six months. In June 2010, bold examination indicated an elevated level of tumor marker CA19-9. Computed tomography (CT) and positron emission tomography (PET)/CT revealed Virchow's and para-aortic lymph node metastasis. Therapy with XELOX and bevacizumab (Bmab) was administered and continued for 10 cycles. Capecitabine+Bmab treatment was also administered for 11 courses due to an adverse event of peripheral neuropathy. Follow-up revealed both the Virchow's and para-aortic lymph node metastasis had disappeared upon completion of treatment. In November, 2011 the patient was considered to have achieved a clinical complete response (CR) and continues to be followed with no further disease progression.
authors.affiliation: Dept. of Coloproctological Surgery, Faculty of Medicine, Juntendo University.
authors.forename: Shingo
authors.initials: S
authors.lastname: Ito
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Ichikawa
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Kure
authors.forename: Kumpei
authors.initials: K
authors.lastname: Honjo
authors.forename: Jun
authors.initials: J
authors.lastname: Aoki
authors.forename: Yu
authors.initials: Y
authors.lastname: Okazawa
authors.forename: Kosuke
authors.initials: K
authors.lastname: Mizukoshi
authors.forename: Hisashi
authors.initials: H
authors.lastname: Ro
authors.forename: Masaya
authors.initials: M
authors.lastname: Kawai
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Takehara
authors.forename: Haruna
authors.initials: H
authors.lastname: Okubo
authors.forename: Shun
authors.initials: S
authors.lastname: Ishiyama
authors.forename: Kiichi
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Komiyama
authors.forename: Makoto
authors.initials: M
authors.lastname: Takahashi
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Yaginuma
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kojima
authors.forename: Michitoshi
authors.initials: M
authors.lastname: Goto
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Tomiki
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Sakamoto
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D000069287:Capecitabine; D002430:Cecal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008207:Lymphatic Metastasis; D010071:Oxaloacetates; D012074:Remission Induction
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D010071:Oxaloacetates; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil